Peptide · developed by Pfizer
Berobenatide is a drug administered by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07932925 | Phase 3 | Urinary Incontinence, Stress | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Overweight and/or ObesityUrinary Incontinence, Stress
Updated Nov 22, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →